RT Journal Article
SR Electronic
T1 Dabigatran: Will it change clinical practice?
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 657
OP 664
DO 10.3949/ccjm.78a.11021
VO 78
IS 10
A1 Siddharth A. Wartak
A1 John R. Bartholomew
YR 2011
UL http://www.ccjm.org/content/78/10/657.abstract
AB Dabigatran (Pradaxa) is a new oral anticoagulant approved in the United States for the primary prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation. It offers clinicians an alternative to warfarin (Coumadin), and it has received considerable interest because of its convenience of use, clinical efficacy, and safety profile. However, it is more expensive, and this may limit its widespread use.